Regulatory

Ascelia Pharma publishes Annual Report for 2020

2021-03-30
Download

Ascelia Pharma’s Annual Report has now been published and is available on the company’s website.

"In 2020, despite the ongoing Covid-19 pandemic, we continued to advance the clinical development program and commercial preparations of our novel Phase 3 contrast agent Mangoral. We also accelerated the Phase 2 preparations for our oral chemotherapy tablet Oncoral.

Our focus in 2021 is on the ongoing Phase 3 study SPARKLE, the preparations to make Mangoral available to patients in need, and to initiate the clinical Phase 2 for Oncoral. We work constantly to create stakeholder value, and the development in 2020 un­derlines the progress we have made”, said Magnus Corfitzen, CEO at Ascelia Pharma.

2021-05-12

Quarterly Report Q1 2021: US office opened in preparation of launch

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q1 2021 (January – March 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations
2021-05-05

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Today, on 5 May 2021, the annual general meeting was held in Ascelia Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
2021-04-30

Number of shares and votes in Ascelia Pharma AB